Literature DB >> 17069263

A case of postpartum cerebral venous thrombosis.

Betty Cole1, Laura M Criddle.   

Abstract

Cerebral venous thrombosis, also known as cortical venous, cerebral sinus, cerebral venous sinus, or dural sinus thrombosis, results from clot formation in one of the many outflow tracts of the brain. Obstruction of flow causes venous hypertension, which is responsible for clinical findings associated with this condition. Signs and symptoms of cerebral venous thrombosis include headache, nausea, mental status changes, seizures, and focal neurologic deficits. Although cerebral venous thrombosis can occur at any time during life, women are particularly vulnerable before delivery and during the postpartum period because of the hypercoagulable state that accompanies pregnancy. This case study describes the challenging clinical course of one postpartum patient who developed venous thrombosis of the sagittal sinus.

Entities:  

Mesh:

Year:  2006        PMID: 17069263     DOI: 10.1097/01376517-200610000-00005

Source DB:  PubMed          Journal:  J Neurosci Nurs        ISSN: 0888-0395            Impact factor:   1.230


  3 in total

1.  Cerebral Venous Thrombosis in Pregnancy-A Poignant Allegory of an Unusual Case.

Authors:  Sheeba Marwah; Gaikwad Harsha Shailesh; Sumedha Gupta; Manjula Sharma; Pratima Mittal
Journal:  J Clin Diagn Res       Date:  2016-12-01

2.  [Unusual post-partum cerebral thrombophlebitis].

Authors:  Moulay Elmehdi Elhassani; Abdellah Baba Habib; Jaouad Kouach; Youssef Sekkach; Hicham Bakkali; Mohamed Jira; Mohamed Elqatni; Ali Abouzahir; Dris Ghafir; Dris Moussaoui; Mohamed Dehayni
Journal:  Pan Afr Med J       Date:  2014-08-21

3.  Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data.

Authors:  Hikmat Abdel-Razeq; Baha' Sharaf; Rama AlMasri; Rashid Abdel-Razeq; Faris Tamimi; Omar Khader; Osama Salama; Mahmoud Abunasser; Sarah Edaily; Hazem Abdulelah
Journal:  Cancer Manag Res       Date:  2022-03-08       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.